C4 Therapeutics

Updated Data in Multiple Myeloma and First Data in Non-Hodgkin's Lymphoma from the Ongoing Cemsidomide Phase 1/2 Trial

American Hematology Annual Meeting (ASH)

December 8, 2024

Forward-looking Statements and Intellectual Property

FORWARD-LOOKING STATEMENTS

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward-looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

INTELLECTUAL PROPERTY

C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.

Today's Agenda

Introductions	Courtney Solberg, Senior Manager of IR
Opening Remarks	Andrew Hirsch, President and CEO
Cemsidomide Phase 1 MM & NHL Data & Next Steps	Len Reyno, M.D., CMO
Concluding Remarks & Q&A Session	Andrew Hirsch, President and CEO Len Reyno, M.D., CMO Kendra Adams, CFO

C4 Therapeutics

Opening Remarks

Andrew Hirsch
President and Chief Executive Officer

C4 Therapeutics

C4T Has Delivered a Steady Flow of Clinical Updates and Innovative Collaborations Over the Past 12 Months…

Significant Progress Across Clinical Programs

Cemsidomide

- ✓ Compelling activity in both multiple myeloma and non-Hodgkin's lymphoma
- ✓ Modest and manageable neutropenia
- ✓ Emerging data demonstrate positive exposure-response relationship
- ✓ Evidence of immunomodulatory effects, consistent with the class

CFT1946

- ✓ Monotherapy anti-tumor activity, including tumor reductions across various V600 mutation types
- ✓ Dose-dependent bioavailability
- ✓ Well-tolerated; no Grade ≥ 3 cutaneous adverse events commonly seen with BRAF inhibitors
- ✓ Preclinical data demonstrate ability to cross blood-brain barrier

CFT8919

- ✓ Clinical trial initiated in Greater China in partnership with Betta Pharmaceuticals

Collaborations Have Further Validated TORPEDO Platform

Biogen

- ✓ Delivered two development candidates for non-oncology targets

MERCK

- ✓ Established partnership to discover and develop degrader antibody conjugates

Merck KGaA
Darmstadt, Germany

- ✓ Announced collaboration to discover targeted protein degraders against critical oncogenic proteins

…Which Set the Stage to Unlock Value

VALUE DRIVERS	KEY CATALYSTS
Cemsidomide IKZF1/3	Further development in multiple myeloma and non-Hodgkin's lymphoma positions cemsidomide to potentially be best-in-class IKZF1/3 degrader
CFT1946 BRAF V600 Mutant	Phase 1 data updates to further validate initial anti-tumor activity and safety profile in melanoma and colorectal cancer
CFT8919 EGFR L858R	Phase 1 data from Greater China clinical trial to inform US and rest-of-world development plans
TORPEDO Platform	Develop orally bioavailable degraders in oncology and non-oncology targets through internal research and collaborations

C4T is positioned to become a **fully integrated biotechnology** company focused on **orally bioavailable degraders**

Cemsidomide First-in-Human Clinical Program

Relapsed Refractory Multiple Myeloma and Non-Hodgkin's Lymphoma

C4 Therapeutics

IKZF1/3 Are Key Promoters of Myeloma and Lymphoma Cell Survival and Will Remain Important Therapeutic Targets in MM and NHL



Key Roles of IKZF1/3

Physiological Functions:

- **IKZF1/3** are key transcriptional regulators of hematopoietic stem cell differentiation
- **IKZF1/3** directly regulate the activity of **IRF4**, another transcription factor that regulates downstream immune cell differentiation

Oncogenic Functions:

- Multiple myeloma and lymphoma cells rely on **IKZF1/3** and **IRF4** for survival

IKZF1/3 Degradation Leads to:

- Downregulation of **IRF4**, promoting the death of myeloma and lymphoma cells
- On-target neutropenia

Multiple myeloma (MM); non-Hodgkin's lymphoma (NHL)

C4 Therapeutics

Cemsidomide First-in-Human Phase 1 Trial Continues to Progress

Data to date reinforce potential of drug to become best-in-class IKZF1/3 degrader used as a backbone therapy of choice

PHASE 1 DOSE ESCALATION TRIAL

2022

R/R MM
Monotherapy

Dosing: QD

21 days on/
7 days off

N=5

Status: Complete

2023

R/R MM
Monotherapy

Dosing: MWF & QD

14 days on/
14 days off

N=22

Status: Complete

- 14 days on/14 days off established as an effective dosing schedule
- Demonstrated monotherapy anti-myeloma and immunomodulatory effects supporting combination with other anti-myeloma agents

ASH 2024

R/R MM
Dex Combo

Dosing: MWF & QD

14 days on/
14 days off

N=~40

Status: Enrolling

- Well-tolerated with manageable neutropenia and low rates of infections and febrile neutropenia
- Wide therapeutic index with anti-myeloma activity across a broad range of doses

R/R NHL
Monotherapy

Dosing: MWF & QD

14 days on/
14 days off

N=~25

Status: Enrolling

- Well-tolerated with additional dose finding ongoing
- Compelling anti-lymphoma activity across a broad range of doses in PTCL

Monday, Wednesday, Friday dosing (MWF); once daily (QD); peripheral T-cell lymphoma (PTCL); relapsed refractory multiple myeloma (R/R MM); relapsed refractory non-Hodgkin's lymphoma (R/R NHL)

C4 Therapeutics

Multiple Myeloma

Cemsidomide + Dexamethasone

C4 Therapeutics

With a Potentially Best-in-Class Profile, Cemsidomide Is Positioned to Be an IKZF1/3 Degrader of Choice Across Various Combinations

EVOLVING MULTIPLE MYELOMA TREATMENT LANDSCAPE

U.S. Addressable Patients (2024)	~33,000[1]	~29,000	~25,000	~20,000	≤12,000
Treatment Line	1L	2L	3L	4L	5L+



CEMSIDOMIDE OPPORTUNITY

- IKZF1/3 degraders are currently used across lines of therapy, from post-transplant maintenance to 5L+ doublets, and will remain backbone therapies in various combination approaches
- **Cemsidomide has the potential to become the IKZF1/3 degrader of choice** in numerous regimens across lines of therapy given its potent anti-myeloma activity, differentiated safety profile, and immunomodulatory effects

[1]Approximately 30% of multiple myeloma patients undergo a hematopoietic stem cell transplant and receive post-transplant maintenance therapy.
[2]Other MOAs approved in MM include anti-SLAMF7 mAbs and XPO1 inhibitors and potential future treatment options include FcRH5 bispecific T-cell engagers, BCL-2 inhibitors, and others.
Sources: NCI SEER, NCCN guidelines, consulting engagements with Health Advances and Clearview.
B-cell maturation antigen (BCMA); G protein-coupled receptor, class C, group 5, member D (GPRC5D); monoclonal antibodies (mAbs); mechanism of action (MOA)

Cemsidomide + Dexamethasone Dose Escalation Trial in MM Continues to Progress; Have Not Exceeded the Maximum Tolerated Dose

KEY INCLUSION CRITERIA

- Adults with MM, R/R to at least 3 prior lines of therapy that have included lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid, and an anti-CD38 monoclonal antibody
- Nonresponsive to or progressed within 60 days of prior therapy
- Creatinine clearance ≥40 mL/min
- ECOG ≤2

Phase 1 Study Endpoints

- **Primary:** assess safety, tolerability and define the RP2D/MTD
- **Secondary:** assess PK, PD, and preliminary anti-tumor activity

DOSE ESCALATION
CEMSIDOMIDE 14/14 + DEX*

Utilizing a Bayesian logistic regression model until determination of the MTD and/or RP2D



*Cemsidomide administered as 14 days on/14 days off in a 28-day cycle; Dex was dosed on days 1, 8, 15, and 22 at doses of 40 mg orally for patients ≤75 years old and 20 mg orally for patients >75 years old; 2 patients at 100 µg are excluded as they had not completed Cycle 1 as of the data cut off date.

[a]DLT at 62.5 µg QD was due to Grade 4 neutropenia lasting >7 days.

Eastern Cooperative Oncology Group (ECOG); maximum tolerated dose (MTD); Monday Wednesday Friday (MWF); multiple myeloma (MM); once daily (QD); pharmacodynamics (PD); pharmacokinetic (PK); recommended Phase 2 dose (RP2D); relapsed refractory (R/R)

C4 Therapeutics

Data cutoff: 10/11/24

Heavily Pre-Treated Patient Population With Majority Having Received Prior CAR-T, BCMA, or T-Cell Engager Therapy

Baseline Characteristics

Characteristics	Safety Population (N=47)
Age, median (range)	67 (39-82 years)
Male, n (%)	25 (53)
Years since initial diagnosis, median (range)	7 (2-18)
ECOG performance status, n (%) 0 1 2	 10 (21) 34 (72) 3 (7)
Black or African American, n (%) **White, n (%)** **Other, n (%)**	9 (19) 33 (70) 5 (11)
Revised ISS at screening, n (%) Stage 1 Stage 2 Stage 3 Missing	 21 (45) 15 (32) 5 (11) 6 (13)
Presence of EMD, n (%)	14 (30)

Prior Therapies

Characteristics	Safety Population (N=47)
Prior therapies, median (range)	6 (3-22)
Prior lenalidomide, n (%)	47 (100)
Prior pomalidomide, n (%)	46 (98)
Prior anti-CD38 mAb, n (%)	47 (100)
Prior CAR-T therapy, n (%)	19 (40)
Prior TCE therapy, n (%)	21 (45)
Prior CAR-T or TCE therapy, n (%)	31 (66)
Prior CAR-T and TCE therapy, n (%)	9 (19)
Prior BCMA therapy, n (%)	33 (70)
Triple-class exposed*, n (%)	47 (100)
Penta-class exposed†, n (%)	40 (85)

*Defined as exposed to ≥1 immunomodulatory agent, ≥1 proteasome inhibitor, and 1 anti-CD38 monoclonal antibody.
†Defined as exposed to ≥2 immunomodulatory agents, ≥2 proteasome inhibitors, and 1 anti-CD38 monoclonal antibody.
B-cell maturation antigen (BCMA); Eastern Cooperative Oncology Group (ECOG); extramedullary disease (EMD); International Staging System (ISS); monoclonal antibody (mAb); T-cell engager (TCE)

Data cutoff: 10/11/24

Cemsidomide Was Well-Tolerated With Manageable Neutropenia and No Treatment Emergent Adverse Events Lead to Dose Reductions

- **1 DLT** (Grade 4 neutropenia lasting >7 days at the 62.5 µg dose level)
- **No TEAEs lead to dose reductions**
- **TEAEs leading to dose interruption: 32%** (15/47)
- **TEAEs leading to discontinuation[1]: 4%** (2/47)

Common (>20% All Grades) TEAEs and Events of Interest, n (%)	All Grades (N=47)	Grade 3 (N=47)	Grade 4 (N= 47)	Grade 5 (N=47)
Neutropenia	22 (47)	6 (13)	12 (26)	0
Infections	18 (38)	7 (15)	0	1 (2)
Pneumonia	5 (11)	5 (11)	0	0
Upper respiratory tract infection	7 (15)	1 (2)	0	0
Septic shock	1 (2)	0	0	1 (2)
Anemia	17 (36)	10 (21)	0	0
Fatigue	14 (30)	0	0	0
Thrombocytopenia	10 (21)	3 (6)	2 (4)	0
Diarrhea	10 (21)	0	0	0
Lymphopenia	9 (19)	6 (13)	0	0
Febrile neutropenia	3 (6)	3 (6)	0	0

2 patients experienced Grade 5 AEs (septic shock and subdural hematoma), both deemed unrelated to cemsidomide

[1]Primary reason of discontinuation of patient at 37.5 µg was due to withdrawal of consent; primary reason of discontinuation of patient at 75 µg was due to death unrelated to cemsidomide.
Adverse events (AEs); dose limiting toxicity (DLT); treatment emergent adverse events (TEAEs)

C4 Therapeutics

Data cutoff: 10/11/24

Grade ≥3 Neutropenia, Febrile Neutropenia and Infections Were Infrequent and Rates Did Not Increase With Higher Cemsidomide Doses

Common Hematologic and Infection Grade ≥3 TEAEs, n (%)	50 µg MWF (N=6)	37.5 µg QD (N=12)	62.5 µg QD (N=15)	75 µg QD (N=14)	Total (N=47)
Neutropenia	2 (33)	6 (50)	6 (40)	4 (29)	18 (38)
Anemia	1 (17)	3 (25)	3 (20)	3 (21)	10 (21)
Infections	0	4 (33)	1 (7)	3 (21)	8 (17)
Upper respiratory tract infection	0	0	0	1 (7)	1 (2)
Pneumonia	0	3 (25)	1 (7)	1 (7)	5 (11)
Septic shock	0	0	0	1 (7)	1 (2)
Thrombocytopenia	2 (33)	1 (8)	1 (7)	1 (7)	5 (11)
Lymphopenia	0	4 (33)	2 (13)	0	6 (13)
Febrile neutropenia	1 (17)	2 (17)	0	0	3 (6)

Once daily (QD); Monday Wednesday Friday (MWF); treatment emergent adverse events (TEAEs)

C4 Therapeutics

Data cutoff: 10/11/24

Compelling Cemsidomide Safety Profile With Low Rates of Neutropenia and Infections With Limited G-CSF Use

Rates of Neutropenia, Infections, and G-CSF Use by Cycle



Total Pts	47	42	34	22	15	10	7	6

- **Only 26% (12/47) of pts received G-CSF** across the study
- **Only one patient experienced Grade ≥3 neutropenia for the first time after completing cycle 2**

Notes: No cases of Grade ≥3 neutropenia were recorded after Cycle 7. One patient experienced a Grade ≥3 infection in a Cycle >8. G-CSF use was not permitted during Cycle 1 in escalation cohorts. One patient in the 50 µg MWF cohort came off study during Cycle 1 and received G-CSF after treatment was discontinued. No patients received G-CSF after Cycle 7.
The same patients that experienced neutropenia at Cycle 5 and Cycle 7, also received G-CSF.
Adverse events (AEs); granulocyte colony-stimulating factor (G-CSF); patients (PTs)

C4 Therapeutics

Data cutoff: 10/11/24

Across Doses, 40% (14/35) of Multiple Myeloma Patients With Elevated Light Chains Demonstrated at Least a 50% Decrease in dFLC

Dose Proportional Exposure



- Overall geometric mean half-life estimate is approximately 2 days

Best Change in dFLC from Baseline (Cemsidomide + Dex)

*Multiple Myeloma Patients w/ Elevated Light Chain Disease (N=35)**



- **69% (24/35)** of patients with elevated light chain disease demonstrated a **decrease in dFLC**

*Only included treated patients who meet both criterion (A) and (B). (A) baseline kappa free light chain value >19.4 mg/L or baseline lambda free light chain value >26.3 mg/L. (B) ratio of baseline free light chain kappa over baseline free light chain value lambda >4:1 or <1:2.

Difference in involved and uninvolved free light chain (dFLC); once daily (QD); Monday Wednesday Friday (MWF); multiple myeloma (MM); pharmacokinetic (PK)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide 75 µg Dose Level or Greater Drives Sufficient Exposure Resulting in Meaningful Reductions in Light Chains



Exposure (AUC) Quartiles

	<Q1 (N=9)	Q1-Q2 (N=8)	Q2-Q3 (N=8)	>Q3 (N=9)
Mean $AUC_{0\text{-}28d}$ (ng*h/mL)	14.6	28.8	37.9	**65.2**
Mean Change in dFLC from Baseline	+10%	-12%	-20%	**-53%**
Cemsidomide + Dex Dose	**~17 µg** QD	**~35 µg** QD	**~45 µg** QD	**~78 µg** QD

N=34 with abnormal baseline sFLC defined as (A) kappa FLC >19.4 mg/L or lambda FLC >26.3 mg/L and (B) kappa-to-lambda FLC ratio >4 or <0.5.
Cemsidomide dose was back-calculated based on the population PK model.
Area under the curve (AUC); difference in involved and uninvolved free light chain (dFLC); maximum response (Emax); Monday Wednesday Friday (MWF); once daily (QD); population pharmacokinetics (popPK); pharmacokinetic (PK)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide Demonstrated Anti-Myeloma Activity Across Dose Levels



As of the data cutoff:

- **26% ORR** and **40% clinical benefit rate across all dose levels** evaluated
- At the two highest dose levels evaluated to date (62.5 µg and 75 µg), **62% of all patients remain on treatment**[1]

[a]1 patient in the 37.5 µg cohort achieved a PR based on light chains, no follow up M protein available; 1 patient in the 62.5 µg cohort had an unconfirmed PR as of the data cutoff date; 1 patient in the 75 µg cohort had an unconfirmed PR as of the data cutoff date.
[b]Patient came off study due to unrelated death. [1] Includes all 47 patients, including only safety evaluable patients.
Complete response (CR); minimal response (MR); Monday Wednesday Friday (MWF); non-evaluable (NE); once daily (QD); partial response (PR); progressive disease (PD); stable disease (SD); stringent complete response (sCR); T-cell-engaging antibodies (TCE); very good partial response (VGPR); Clinical Benefit Rate (≥ MR) (CBR)

C4 Therapeutics

Data cutoff: 10/11/24

75 µg Cemsidomide Dose Level Resulted in Compelling Anti-Myeloma Activity With a 36% ORR and 45% CBR

Best Response: Multiple Myeloma – Cemsidomide + Dex*



*Investigator assessed response

[a]1 patient in the 37.5 µg cohort achieved a PR based on light chains, no follow up M protein available; 1 patient in the 62.5 µg cohort had an unconfirmed PR as of the data cutoff date; 1 patient in the 75 µg cohort had an unconfirmed PR as of the data cutoff date.

Minimal response (MR); Monday Wednesday Friday (MWF); once daily (QD); partial response (PR); progressive disease (PD); stable disease (SD); stringent complete response (sCR); very good partial response (VGPR)

Overall Response Rate (≥ PR) (ORR); Clinical Benefit Rate (≥ MR) (CBR)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide's Differentiated Safety Profile Is Well Suited for Combination Studies, Potentially Resulting in Fewer Disruptive Adverse Events

Cemsidomide + Dex
Key Grade ≥3 Adverse Events



Mezigdomide + Dex[1]
Key Grade ≥3 Adverse Events



Cross trial comparisons only to be used as benchmarks for relative comparison

[1]Richardson 2023 NEJM.
*Mezigdomide recommended Phase 2 dose expansion dose was 1.0 mg daily dosing (QD) 21 days on/7 days off.
Note: All cases of febrile neutropenia in the cemsidomide trial were Grade 3. In the mezigdomide dose escalation and expansion cohorts, febrile neutropenia splits between Grade 3/4 were 5%/4% and 13%/2% ,respectively.

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide Has the Potential to Be a Backbone Therapy of Choice Where IKZF1/3 Degradation Is Warranted

Cemsidomide + dex demonstrated compelling anti-myeloma activity across a broad range of doses, highlighting a wide therapeutic range

- 36% ORR at the highest dose level evaluated to date (75 µg QD)
- 26% ORR across all dose levels

Cemsidomide + dex was well-tolerated with a compelling safety profile

- 38% of patients experienced Grade 3/4 neutropenia, which was manageable, and no cases resulted in cemsidomide discontinuation

75 µg is a target dose for various + dex regimens with potential for higher doses to also be considered for development as dose escalation continues

- For immune-based combination strategies, doses lower than 75 µg are optimal based on anti-myeloma activity and immune activation observed in the monotherapy data set[1]

Cemsidomide is well suited for further development across treatment lines and in combination with other anti-myeloma agents

[1]Monotherapy cemsidomide dataset in multiple myeloma was presented in December 2023
Once daily (QD); overall response rate (ORR)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide's Profile Supports Development Across Multiple Lines of Treatment in MM, Estimated to Be ~$42B Market Opportunity by 2030[1]

INITIAL COMBINATION TRIALS:

Prior Lines of Therapy	*Trial Design*
1 – 3	**Cemsidomide + BCMA bispecific[2]** - Safety dose escalation followed by Phase 2 expansion
2 – 4 (Post anti-BCMA therapy)	**Cemsidomide + anti-CD38[3] + dex** - Safety dose escalation followed by Phase 2 expansion

Additional Combinations
(not exhaustive):

- **Proteasome inhibitors** (bortezomib, carfilzomib, ixazomib)
- **GPRC5D bispecifics** (talquetamab, RG6234)
- **BCMA ADC** (bela-maf)
- **FcRH5 bispecific** (cevostamab)
- **Anti-SLAMF7** (elotuzumab)
- **XPO1 inhibitor** (selinexor)
- **CAR-T maintenance**

NEXT STEPS:

- **Complete Phase 1 dose escalation trial** in multiple myeloma to establish go forward doses
- **Initiate initial combination trials**
- **Engage regulatory authorities** on registrational path

[1]Source: Evaluate Pharma - Multiple myeloma market opportunity
[2]Could choose from approved BCMA bispecifics teclistamab or eltranatamab. Also other BCMA bispecifics in development (e.g., linvoseltamab).
[3]Could choose from approved anti-CD38 antibodies daratumumab or isatuximab.
Antibody-drug conjugates (ADC); B-cell maturation antigen (BCMA); maximum tolerated dose (MTD); multiple myeloma (MM)

C4 Therapeutics

Non-Hodgkin's Lymphoma (NHL)

Monotherapy Cemsidomide

C4 Therapeutics

Cemsidomide Has the Potential to Be Developed Across NHL Subtypes and Lines of Treatment

	B-Cell Lymphomas				T-Cell Lymphomas
	DLBCL Diffuse Large B-Cell Lymphoma	**FL** Follicular Lymphoma	**MZL** Marginal Zone Lymphoma	**MCL** Mantle Cell Lymphoma	**PTCL Subtypes** Peripheral T-Cell Lymphoma
U.S. Annual Incidence (2023)[1]	~26,000	~15,000	~5,000	~4,000	~5,000
Lenalidomide FDA Approved[2]	✓	✓	✓	✓	
Lenalidomide in NCCN Guidelines	✓	✓	✓	✓	✓

Cemsidomide Opportunity

- IKZF1/3 degraders (e.g., lenalidomide) are widely used across NHL subtypes
- Cemsidomide has the potential to be developed as a **monotherapy in the R/R setting** and in **combination with frontline standard of care regimens**

[1]SEER, American Cancer Society, Lymphoma Research Foundation.
[2]FL, MZL, and MCL FDA approved in the Revlimid (lenalidomide) label and DLBCL approved in the Monjuvi (tafasitamab) label.
U.S. Food and Drug Administration (FDA); National Comprehensive Cancer Network (NCCN); non-Hodgkin's lymphoma (NHL); relapsed refractory (R/R)

C4 Therapeutics

Dose Exploration Continues for the Cemsidomide Monotherapy Dose Escalation Trial in R/R NHL

KEY INCLUSION CRITERIA

- Adults with NHL, R/R to prior therapy
  - PTCL patients must have received at least 1 prior alkylator-based chemotherapy
  - ALCL patients must have also received a CD-30 mAb
- Nonresponsive to or progressed within 60 days of prior therapy
- Creatinine clearance ≥40 mL/min
- ECOG ≤2

Phase 1 Study Endpoints

- **Primary:** assess safety, tolerability and define the RP2D/MTD
- **Secondary**: assess PK, PD, and preliminary anti-tumor activity

DOSE ESCALATION CEMSIDOMIDE 14/14

Utilizing a Bayesian logistic regression model until determination of the MTD and/or RP2D



BACK-FILL COHORT(S)

37.5 µg QD
Back-fill cohort; N=4

PHASE 2

Phase 2 Expansion

Anaplastic large cell lymphoma (ALCL); dose escalation meeting (DEM); dose limiting toxicities (DLT); Eastern Cooperative Oncology Group (ECOG); monoclonal antibody (mAb); maximum tolerated dose (MTD); Monday Wednesday Friday (MWF); non-Hodgkin's lymphoma (NHL); once daily (QD); pharmacodynamic (PD); pharmacokinetic (PK); peripheral T-cell lymphoma (PTCL); recommended Phase 2 dose (RP2D); relapsed refractory (R/R)

C4 Therapeutics

Data cutoff date: 10/11/2024

Heavily Pre-Treated Population Where Majority of Patients Were Diagnosed With PTCL, Reflecting High Unmet Need

Characteristics	Safety Population (N=23)
Age, median (range)	68 (28-85 years)
Male, n (%)	14 (61)
Years since initial diagnosis, median (range)	2 (0.4-21)
ECOG performance status, n (%)	
0	11 (48)
1	9 (39)
2	2 (9)
Missing	1 (4)
Black or African American, n (%)	6 (26)
White, n (%)	13 (57)
Other, n (%)	4 (17)
IPI at screening, n (%)	
1	2 (9)
2	6 (26)
3	7 (30)
4	3 (13)
Missing	5 (22)

Characteristics	Safety Population (N=23)
Prior therapies, median (range)	3 (1-14)
1	2 (9)
2	7 (30)
3	3 (13)
≥4	11 (48)
PTCL, n (%)	17 (74)
PTCL-NOS	5 (22)
AITL	4 (17)
ALCL	3 (13)
ATLL	5 (22)
B-cell lymphoma, n (%)	6 (26)
DLBCL	4 (17)
MCL	1 (4)
MZL/MALT	1 (4)
Prior CAR-T therapy, n (%)	4 (17)
Prior HCT, n (%)	4 (17)
Autologous	3 (13)
Allogenic	1(4)

Angioimmunoblastic T-cell lymphoma (AITL); anaplastic large cell lymphoma (ALCL); adult T-cell leukemia/lymphoma (ATLL); diffuse large B-Cell lymphoma (DLBCL); Eastern cooperative oncology group (ECOG); hematopoietic cell transplantation (HCT); International Prognostic Index (IPI); mantle cell lymphoma (MCL); marginal zone lymphoma/mucosa-assisted lymphoid tissue (MZL/MALT); peripheral T-cell lymphoma (PTCL); PTCL-not otherwise specified (PTCL-NOS)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide Was Well-tolerated With Manageable Incidents of On-target Neutropenia

- **2 DLTs occurred at 100 µg QD** (Grade 4 thrombocytopenia and Grade 3 febrile neutropenia)
- **TEAEs leading to discontinuation: 9%** (2/23)
- **39% (9/23) of patients received G-CSF**
  - 3 of 9 patients received G-CSF in Cycle 1

Common (>20% All Grades) TEAEs and Events of Interest*, n (%)	All Grade (N=23)	Grade 3 (N=23)	Grade 4 (N=23)
Infections	15 (65)	4 (17)	2 (9)
Upper respiratory tract infection	4 (17)	0	0
Sepsis	1(4)	0	1 (4)
Bacteremia	1(4)	0	1 (4)
Pneumonia	2 (9)	2 (9)	0
Neutropenia	11 (48)	4 (17)	7 (30)
Fatigue	11 (48)	1 (4)	0
Cough	7 (30)	0	0
Anemia	6 (26)	4 (17)	0
Peripheral edema	5 (22)	0	0
Febrile neutropenia*	4 (17)	4 (17)	0
Thrombocytopenia*	4 (17)	1 (4)	2 (9)
Maculopapular rash*	3 (13)	2 (9)	0

One patient experienced a Grade 5 AE (hip fracture resulting in transfer to hospice)

*Events of Interest
Adverse event (AE); dose limiting toxicities (DLTs); granulocyte colony-stimulating factor (G-CSF); once daily (QD); treatment emergent adverse events (TEAEs)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide Monotherapy Adverse Events by Dose Level

Common Grade ≥3 TEAEs, n (%)	25 µg MWF (N=3)	50 µg MWF (N=3)	37.5 µg QD (N=9)	62.5 µg QD (N=4)	100 µg QD (N=4)	Total (N=23)
Neutropenia	0	0	5 (56)	4 (100)	2 (50)	11 (48)
Infections	0	0	3 (33)	0	3 (75)	6 (26)
Pneumonia	0	0	1 (11)	0	1 (25)	2 (9)
Sepsis	0	0	1 (11)	0	0	1 (4)
Urinary tract infection	0	0	1 (11)	0	0	1 (4)
Bacteremia	0	0	0	0	1 (25)	1 (4)
Skin infection	0	0	0	0	1 (25)	1 (4)
Anemia	0	0	3 (33)	0	1 (25)	4 (17)
Febrile neutropenia	0	0	1 (11)	1 (25)	2 (50)	4 (17)
Thrombocytopenia	0	0	1 (11)	0	2 (50)	3 (13)
Maculopapular rash	0	0	1 (11)	1 (25)	0	2 (9)

Once daily (QD); Monday Wednesday Friday (MWF); Treatment Emergent Adverse Events (TEAEs)

C4 Therapeutics

Data cutoff: 10/11/24

Clinical Responses Were Observed Across a Broad Range of Doses



[a] Both patients were not evaluable based on PET-CT but were considered progressive disease due to CT scan.
[b] Both patients dose reduced to 62.5 ug following DLTs.

Anaplastic large cell lymphoma (ALCL); adult T-cell leukemia/lymphoma (ATLL); angioimmunoblastic T-cell lymphoma (AITL); complete metabolic response rate (CMR); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); marginal zone lymphoma/mucosa-assisted lymphoid tissue (MZL/MALT); Monday Wednesday Friday (MWF); non-evaluable (NE); once daily (QD); overall response rate (ORR); partial metabolic response (PMR); peripheral T-cell lymphoma (PTCL); PTCL-not otherwise specified (PTCL-NOS); progressive metabolic disease (PMD); stable disease (SD)

Data cutoff: 10/11/24

Compelling and Deep Responses Achieved Across PTCL Subtypes



- Cemsidomide monotherapy **produced responses in all four PTCL subtypes**
- **All AITL patients (4/4)** experienced **a metabolic response**

*Investigator assessed response; 2 patients were evaluated based on CT scan and were PD but not evaluable based on PET-CT, both patients are included as PMD for PET-CT based assessment; 2 additional subjects that came off study prior to follow up scans were not considered efficacy evaluable.
Angioimmunoblastic T-cell lymphoma (AITL); anaplastic large cell lymphoma (ALCL); adult T-cell lymphoma (ATLL); complete metabolic response (CMR); overall response rate (ORR); partial metabolic response (PMR); peripheral T-cell lymphoma (PTCL); peripheral T-cell lymphoma not-otherwise specified (PTCL-NOS)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide Is Well-suited for Further Development in Earlier Lines of Treatment and in Combination

Cemsidomide as a single agent demonstrated compelling anti-lymphoma activity across a broad range of doses in PTCL patients, suggesting a wide therapeutic index

- 44% ORR was observed in PTCL with a 25% CMR rate

Cemsidomide was well-tolerated with additional dose finding ongoing

- 2 DLTs at 100 µg (Grade 4 thrombocytopenia) with enrollment at 75 µg currently ongoing
  - Per BLRM, maximum tolerated dose not yet exceeded
- Grade 3/4 neutropenia cases were manageable with no cases resulting in discontinuation

Profile supports cemsidomide's development as a monotherapy in relapsed refractory settings and potentially in combination in NHL subtypes across treatment lines

Bayesian logistic regression model (BLRM); complete metabolic response (CMR); dose limiting toxicities (DLTs); overall response rate (ORR); peripheral t-cell lymphoma (PTCL)

C4 Therapeutics

Data cutoff: 10/11/24

Cemsidomide Profile Supports Development Across Multiple Lines of Treatment in NHL, Estimated to Be ~$30B Market Opportunity by 2030[1]

NEXT STEPS:

- **Complete Phase 1 dose escalation trial in NHL** and identify go forward dose
- **Initiate expansion cohort** for PTCL
- **Engage regulatory authorities** on registrational path

[1]Source: Evaluate Pharma – NHL Market Opportunity: Non-Hodgkin's lymphoma (NHL); peripheral T-cell lymphoma (PTCL)

C4 Therapeutics

Cemsidomide Is Positioned to Potentially Be a Best-in-Class Therapy in Two Distinct Indications with Opportunities Across Multiple Lines of Therapy

IKZF1/3 is a fundamental target for MM and NHL and data supports cemsidomide as a potential backbone therapy within the evolving treatment landscape

- Well-tolerated with a compelling safety profile
- Compelling anti-tumor activity across a range of dose levels

MM Market Opportunity

Estimated **~$42B** by 2030[1]

NHL Market Opportunity

Estimated **~$30B** by 2030[1]

[1]Source: Evaluate Pharma
Multiple myeloma (MM); non-Hodgkin's lymphoma (NHL)

C4 Therapeutics

Q&A

C4 Therapeutics